CAREMM-2306: Advanced Immunotherapy vs. Classical Immunotherapy
A Comparative Study of Retrospective Outcomes Including Efficacy of Therapy Between Advanced Immunotherapy and Classical Immunochemotherapy in Relapsed/Refractory Lymphoma
1 other identifier
observational
2,500
1 country
1
Brief Summary
The goal of this retrospective study is to compare between the case cohort and control cohort. The case cohort consists of lymphoma patients treated with novel immunotherapy regimen including Chimeric antigen receptor T cell therapy, bispecfic antibody, and/or antibody-drug conjugate. The control cohort consists of lymphoma patients who received conventional chemotherapy as standard-of-care The main question\[s\] it aims to answer are:
- Survival times
- Response outcomes
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2023
CompletedFirst Submitted
Initial submission to the registry
December 18, 2023
CompletedFirst Posted
Study publicly available on registry
January 12, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedJanuary 12, 2024
January 1, 2024
2.3 years
December 18, 2023
January 8, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Comparison of Survival Periods Among Groups Comparison of Survival Periods Among Groups
overall survival
Time Frame: Up to 2 years
Secondary Outcomes (1)
Comparison of Progression-Free Survival Periods
Time Frame: Up to 2 years
Other Outcomes (2)
Comparison of Response Rates
Time Frame: Up to 2 years
Comparison of Healthcare Costs
Time Frame: Up to 2 years
Study Arms (2)
T cell engager
Standard-of-care
Interventions
Eligibility Criteria
Patients treated for lymphoma at Catholic Yeouido St. Mary's Hospital and Seoul St. Mary's Hospital from May 2009 to June 2023
You may qualify if:
- Patients diagnosed with malignant lymphoma at Catholic Yeouido St. Mary's Hospital and Seoul St. Mary's Hospital between May 2009 and June 2023.
- Age 19 or older.
- Anti-cancer salvage chemotherpay for the treatment of relapsed/refractory lymphoma.
You may not qualify if:
- Patients suffering from acute leukemia.
- Patients additionally diagnosed with solid cancer (colon cancer, lung cancer, stomach cancer, etc.) during treatment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul, 06591, South Korea
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- clinical professor
Study Record Dates
First Submitted
December 18, 2023
First Posted
January 12, 2024
Study Start
October 1, 2023
Primary Completion
December 31, 2025
Study Completion
December 31, 2025
Last Updated
January 12, 2024
Record last verified: 2024-01
Data Sharing
- IPD Sharing
- Will not share